Aquinnah Pharmaceuticals
Cambridge
About Aquinnah Pharmaceuticals
Aquinnah Pharmaceuticals is focused on an exciting new area of research and development to modulate neurodegenerative stress granules, believed to be important in the pathology of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $19.8M
- Last round: Grant (Jan 2019)
- Website: aquinnahpharma.com
- Phone: +1 617-863-3678
Industries & Categories
Health Care, Hospital, Medical, Pharmaceutical
Canonical: https://fsome.com/organization/aquinnah-pharmaceuticals-60322 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.